Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 5
Submit an article Journal homepage
36
Views
20
CrossRef citations to date
0
Altmetric
Drug Evaluation

Efavirenz for HIV-1 infection in adults: an overview

Claude Fortin CHUM: Hôpital Notre-Dame, UHRESS-Département de Microbiologie médicale et Infectiologie, 1560, rue Sherbrooke Est, Montréal (Québec) H2L 4M1, Canada. [email protected]
&
Veronique Joly Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales-A, 46 Rue Henri-Huchard, 75877 Paris Cedex 18, France. [email protected]
Pages 671-684 | Published online: 10 Jan 2014

References

  • Palelle FJ Jr, Delaney KM, Moorgan AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J. Med. 338,853–860 (1998).
  • Yeni PG, Hammer SM, Hirsh MS, et al. Treatment for adult HIV infection: 2004 Recommendations of the International AIDS Society — USA Panel. J. Am. Med. Assoc. 292(2), 251–266 (2004).
  • ••Recent update on the recommendations ofthe International AIDS Society; very important guidelines.
  • Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 4\(Suppl. 1), S1—S41 (2003).
  • Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51—F58 (1998).
  • Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Them 22(6), 685–708 (2000).
  • Statszewski S, Morales-Ramirez J, Tashima KT, et al Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J. Med. 341(25), 1865–1873 (1999).
  • Tashima K, Staszewski S, Morales-Ramirez J, et al. 3-year durability of response with an efavirenz (EFV)-containing regimen: 144-week follow-up study 006. Program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8–11 July 2001 (Abstract 810).
  • Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J. Med. 349(24), 2293–2303 (2003).
  • •AIDS Clinical Trial Group (ACTG) study, a complicated study from which really interesting data can be drawn concerning efavirenz.
  • Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J. Med. 349(24), 2304–2315 (2003).
  • •ACTG study, a complicated study from which really interesting knowledge can be drawn concerning efavirenz.
  • Albrecht MA, Bosh RJ, Hammer SM, et al Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J. Med. 345(6), 398–407 (2001).
  • Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixeddose zidovudine and lamivudine as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36(5), 1011–1019 (2004).
  • •Recent trial comparing efavirenz and abacavir (one of its major competitors in the protease inhibitor class).
  • Montaner JSG, Saag MS, Barylski C, Siemon-Hryczyk P FOCUS Study: infected patients. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA, 27–30 September 2002 (Abstract H–167).
  • Bartlett JA, Johnson J, Herrera G, et al Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), ampernavir/ritonavir (PI) or stavudine (NRTI): E554001 (CLASS) preliminary 48-week results. Program and Abstracts of the XIV International AIDS Confirence. Barcelona, Spain, 7–12 July 2002 (Abstract TuOrB1189).
  • Gulick RI, Ribaudo HJ, Shikuma CM, et al Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J. Med 350(18), 1850–1861 (2004).
  • •ACTG 5095, an important study, disclosed the weakness of triple nucleoside regimens with abacavir.
  • Nassar N, Armas L, Smillie J, Moreno S, Keiser P. An observational cohort comparison of zidovudine—lamivudine—efavirenz with zidovudine—lamivudine—abacavir in antiretroviral naive individuals. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Tratment. Paris, France, 13–16 July 2003 (Abstract 554).
  • Van Leth F, Phanuphak P, Ruxrungtham K, et al Comparaison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz or both drugs, plus stavudine and lamivudine: a randomized open-label trial. The 2NN study. Lancet 363,1253–1263 (2004).
  • ••Only large, randomized trial comparing the two available non-nucleoside reverse transcriptase inhibitors — answers an important question.
  • Van Leth F, Andrews S, Grinsztjen B, et al Virologic failure in antiretroviral therapy naive patients is only determined by extreme low values of CD4 cells or high values of HIV-1 RNA concentration, not by choice of treatment with nevirapine or efavirenz. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 550).
  • Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish Efavirenz vs. Nevirapine Comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin. Trials 3(3), 186–194 (2002).
  • Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 16(1), 53–61 (2002).
  • Matthews GV, Gileece Y, Mandalia M, et al. Durability of efavirenz compared with nevirapine with long-term follow-up of antiretroviral-naive patient cohort. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 561).
  • Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine and efavirenz-containing regimens in antiretroviral-naive patients: a cohort study. HIV Clin. Trials 3(4), 296–303 (2002).
  • Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 15(18), 2385–2395 (2001).
  • Cozzi-Lepri A, Phillips AN, Monforte d'Aremino A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with two nucleoside analogs in the Italian Cohort Naive Antiretrovirals (ICoNA) study. I. Infect. Dis. 185(8), 1062–1069 (2002).
  • Reyataz®, package insert. Bristol—Myers Squibb, NJ, USA (2004).
  • Esnouf RI, Ren J, Hopkins AL, et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroayl)piperazine (BHAP) U-90152 explain resitance mutations for this non-nucleoside inhibitor. Proc. Nad Acad. Sci. USA 94,3984–3989 (1999).
  • Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus Type 1 mutations selected in patients failing efavirenz combination therapy. Anti microb. Agents Chemother. 44, 2475–2484 (2000).
  • Ren J, Nichols C, Bird L, et al Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mal Biol 312,795–805 (2001).
  • Walmsley SL, Kelly DV, Tseng AL, Humar A, Harrigan PR Non-nucleoside reverse transcriptase inhibitor failure impairs HIV RNA response to efavirenz-containing salvage antiretroviral therapy. AIDS 15(12), 1581–1584 (2001).
  • Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res. Hum. Retroviruses 18(12), 835–838 (2002).
  • Whitcomb JM, Huang W Limoli K, et al . Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 16, F41—F47 (2002).
  • Katzenstein DA, Bosch RJ, Hellmann N, et al. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS 17,821–830 (2003).
  • Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 16, F33—F40 (2002).
  • Shulman N, Zolopa AR, Passaro D, et al Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS is, 1125–1132 (2001).
  • Bosch RJ, Downey GF, Katzenstein DA, et al Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS 17, 2395–2400 (2003).
  • Gazzard B, Pozniak A, Rosenbaum W, et al. An open-label assessment of TMC-125, a new next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS17 (18), F49—F54 (2003).
  • Sankatsing SU, Weverling GJ, Peeters M, et al. TMC125 exerts similar initial antiviral potency as a five-drug triple class antiretroviral regimen. AIDS 17(18), 2623–2627 (2003).
  • Romines K, St Clair M, Hazen R, et al Antiviral characterization of GW8248, a novel benzophenone non-nucleoside reverse transcriptase inhibitor. Program and Abstrac6-ofthe 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 535).
  • Freeman G, Romines K, Chan J, et al. Novel benzophenone non-nucleoside reverse transcriptase inhibitors with unique drug resistance properties. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 538).
  • Sustiva®, package insert. Bristol—Myers Squibb, NJ, USA (2003).
  • Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacoki net. 40(12), 893–905 (2001).
  • Metzner KJ, Bohnoeffer S, Fisher M, et al. Emergence of minor populations of human immunodeficiency virus Type 1 carrying the M184V and L9OM mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188(10), 1433–1443 (2003).
  • Ananworanich J, Nuesch R, Le Braz M, et al. Failures of week on, week off antiretroviral therapies in a randomized trial. AIDS 17, F33—F37 (2003).
  • Taylor S, Allen S, Fidler S, et al. Stop Study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 131). •Poster disclosing interesting information on the pharmacokinetics of efavirenz.
  • Fiske W, Benedek I, Brennan J, et al. Pharmacokinetics of efavirenz in subjects with chronic liver disease. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 31 January-4 February 1999 (Abstract 367).
  • Meynard JL, Lacombe K, Poirier JM, et al. Influence of HCV or HBV infection on efavirenz plasma concentrations in HIV-infected patients. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 837).
  • Maserati R, Villani P, Seminari E, et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 13(7), 870–871 (1999).
  • Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patient with human immunodeficiency virus infection. Clin. Pharmacol Ther. 73(1), 20–30 (2003).
  • Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 15(1), 71–75 (2001).
  • Ribaudo H, Clifford D, Gulick R, et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response and race: results from ACTG A5095/A5097s. Program and Abstracts of the 1 1 th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 132).
  • •Another poster disclosing interesting data on the pharmacokinetics of efavirenz, demonstrating that there is still information to be learnt.
  • Hitti J, Rosenkranz S, Cohn S, et al. Sex and weight as covariates in the pharmacokinetics of efavirenz, indinavir and nelfinavir. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 604).
  • Haas D, Ribaudo H, Kim R, et al. A common CYP2B-variant is associated with efavirenz pharmacokinetics and central nervous system side effects: ACTG study NWCS214. Program and Abstracts of the 1 1 th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 133).
  • ••Original and novel work disclosingaspects of the pharmacogenomics of antiretrovirals. It is likely that there will be an interesting development on this topic in the near future.
  • Langmann P, Weissbrich B, Desh S, et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur. J. Med. Res. 7(7), 309–314 (2002).
  • Acosta EP Pharmacokinetic enhancement of protease inhibitors. J. Acquir. Immune Defic. Syndr. 29\(Suppl. 1), S11—S18 (2002).
  • Wire MB, Ballow C, Preston SL, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz in healthy volunteers. AIDS 18(6), 897–907 (2004).
  • Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med. 162(9), 985–992 (2002).
  • Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV-infection: current status and future directions. AIDS 51,301–308 (2002).
  • Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and managament of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Group. Clin. Infec. Dis. 37, 613–627 (2003).
  • Gerber JG, Rosenkranz S, Fichtenbaum CJ, et al. The effect of efavirenz and nelfinavir on the pharmacokinetics of pravastatin. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 870).
  • Nelson M, Statszewski S, Morales-Ramirez JO, et al. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: post hoc results from Study 006. Program and Abstracts of the 10th European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden, 28–31 May 2000 (Abstract 3–349).
  • Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/n1 and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosupressed Patients). AIDS 16(11), 1554–1556 (2002).
  • Pulido F, Arribas JR, Miro JM, et al. Clinical, virologic and immunologic response to efavirenz or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J. Acquir. Immune Defic. Syndr. 35(4), 343–350 (2004).
  • Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J. Med. 349(11), 1036–1046 (2003).
  • •• Although not a recent study, it is probably the most important study comparing efavirenz, nevirapine and abacavir — a must read.
  • Fisac C, Fumero E, Crespo M, et al. Metabolic changes in patients switching from a protease inhibitor-containing regimen to abacavir, efavirenz or nevirapine: 24 month results of a randomized study. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 78).
  • Molina M, Fetchal F, Joutnot V, et al. Emtricitabine, didanosine and efavirenz once-daily versus continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS 99). Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 37).
  • Katlama C, Rachlis A, Staszewski S, et al. Better virologic suppression after substitution of protease inhibitor with efavirenz in patients with undetecteable viral loads. Program and Abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece, 28–31 October 2001 (Abstract 06).
  • Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavimez in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin. Infect. Dis. 34(4), 504–510 (2002).
  • Patterson P, Krolewiecki A, Ochoa C, et al. A randomized study of treatment simplification with nevirapine or efavirenz in patients responding to a protease inhibitor based combination. Program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8–11 July 2001 (Abstract 58).
  • Garcia-Benayas T, Blanco F, De la Cruz J, Soriano V, Gonzalea-Lahoz J. Benefit in lipid profile after switching protease inhibitors to nevirapine or efavirenz: a 48 week study. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 721).
  • Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir. Then 8(4), 339–346 (2003).
  • Maggiolo F, Migliorini M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir. Them 6(4), 249–253 (2001).
  • Landman R, Schiemann R, Thiam S, et al Once-a-day highly active antiretroviral therapy in treatment naive HIV-1-infected adults in Senegal. AIDS 17(7), 1017–1022 (2003).
  • Molina JM, Noe E, Raffi F, et al Once-daily combination therapy with emtricitabine (FTC), didanosine (ddI) and efavirenz (EFV) in treatment-naive HIV-infected adults: 3 years follow-up of the MONTANA (ANRS 091) trial. Program and Abstracts of the 2nd L4S Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 594).
  • Gazzard BG, DeJesus E, Cahn P, et al. Abacavir (ABC), once daily (OAD) plus lamivudine (3TC) OAD in combination with efavirenz (EFV) is well-tolerated and effective in the treatment of antiretroviral therapy-naive adults with HIV-1 infection (ZODIAC) study: CAN30021. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 14–17 September 2003 (Abstract H–1722b).
  • Stek M, Hirshel B, Benetucci J, et al Comparison of PI-boosted indinavir with efavirenz plus stavudine regimens in EASIER (European And South American study of Indinavir, Efavirenz and Ritonavir). Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 39).
  • Ferre V, Allavena C, Poizot-Martin I, et al. BIKS Study (Lopinavir/Ritonavir-Efavirenz Combination): Complete 24 weeks results. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 36).
  • Boyd M, Duncombe C, Siangphoe U, et al Indinavir/ritonavir 800/100 mg b.i.d. and efavirenz 600 mg qd provides durable salvage for patients with combination nucleoside analogues failure: HIV-NAT 009-72-week follow-up. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 581).
  • Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 4(1), 62–66 (2003).
  • Moyle GJ, Fletcher C, Gazzard BG. Sleep quality and brainwave patterns during efavirenz therapy. Program and Abstracts of the 5th International Workshop on Adverse Drug Reactions ond Lipodystrophy in HIV Paris, France, 8–11 July 2003 (Abstract 138).
  • Allin M, Reeves I, Tennant-Flowers M, Everall I. Frequency of serious psychiatric acverse events with efavirenz. Program and Abstracts of the 5th International Workshop on Adverse Drug Reactions ond Lipodystrophy in HIV Paris, France, 8–11 July 2003 (Abstract 129).
  • Shah MD, BaMerson K. A manic episode associated with efavirenz therapy for HIV-infection. AIDS 17(11), 1713–1714 (2003).
  • Puzantian T Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 22(7), 930–933 (2002).
  • Welch KJ, Morse A. Association between efavirenz and selected psychiatric and neurological conditions. J. Infect. Dis. 185(2), 268–269 (2002).
  • Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin. Infect. Dis. 38(3), 430–432 (2004).
  • Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35(1), 182–189 (2002).
  • Palmon R, Koo BC, Shoultz DA, Dieterich DT Lack of hepatotoxicity associated with non-nucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr 29,340–345 (2002).
  • Reisler R, Servoss JC, Sherman KE, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials: ACTG Liver Diseases Focus Group. Program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8–11 July 2001 (Abstract 43).
  • Dieterich D, Becker S, Fusco J, et al Low incidence of grade 3 or 4 hepatotoxicity in first HAART observations from 1237 patients followed for 1 year. Program and Abstracts of the XIV International AIDS Conference. Barcelona, Spain, 7–12 July 2002 (Abstract 4534).
  • Imperiale S, Lanes S, Stern J, et al. TARGRT: incidence of elevated AST/ALT with HAART in large observational cohort. Program and Abstracts of the 6th International Congress on Drug Therapy in HIV Infiction, Glasgow, UK, 17–21 November 2002 (Abstract P150).
  • Friss-Moller N, Kirk O, Reiss P, et al. Safety of non-nucleoside reverse transcriptase therapy: data from the EuroSIDA study. Program and Abstracts of the 5th International Workshop on Adverse Drug Reactions ond Lipodystrophy in HIV Paris, France, 8–11 July 2003 (Abstract 24).
  • Dieterich D, Robinson P, Love J, Stern O. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. 38(S2), S80-S89 (2004).
  • Carr A, Samaras K, Thorisdottir A, et al Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 353, 2093–2099 (1999).
  • Tashima K, Stryker R, Skiest D, et al. Lipid profiles and clinical lipodystrophy in Study 006 patients. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA, 26–29 September 1999 (Abstract 1304).
  • Dube M, Zackin R, Parker P, et al. Prospective study of glucose and lipid metabolism in antiretroviral-naive subjects randomized to receive nelfinavir, efavirenz or both combined with zidovudine and lamivudine or didanosine and stavudine: A5005s, a substudy of ACTG 384. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8–11 February 2004 (Abstract 74).
  • Tashima K, Morales-Ramirez JO, Butcher D, et al Abdominal CT-scan substudy of study DPC-006. Program and Abstracts of the 3rd European Workshop on Lipodystrophy and Metabolism Disorders. Marbella, Spain, 25–27 April 2002 (Abstract 0–13).
  • Van Leth F, Phanuphak P, Gazzard B, et al Lipid changes in randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined with stavudine and lamivudine (The 2NN study). Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infection. Boston, USA, 10–14 February 2003 (Abstract 752).
  • Schamberlan M, Benson CA, Carr A, et al Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Sociaty-USA Panel. J. Acquir Immune Defic. Syndr. 31,257–275 (2002).
  • De Santis M, Carducci B, De Santis L, et al Periconceptional exposure to efavirenz and neural tube defects. Arch. Intern. Med. 162(3), 355 (2002).
  • Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16(2), 299–300 (2002).

Websites

  • Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents www.aidsinfo.nih.govllguidelines/adult/AA_ 032304.pdf (Accessed September 2004)
  • Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommandations for Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the USA aidsinfo.nih.gov/guidelines/perinatal/PER_0 62304.pdf (Accessed September 2004)
  • The Antiretroviral Pregnancy Registry www.apregistry.com/who.htm (Accessed September 2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.